Navigation Links
FDA, NIH and Genzyme Reveal Their Strategies to Overcome Viral Contamination at the Pathogen Safety Summit
Date:9/5/2012

LONDON, September 6, 2012 /PRNewswire/ --

Leading biotech and biopharma organisations are coming together to learn how to maximise their viral security strategies and the new technologies available from the FDA, NIBSC, NIH and a range of industry experts including Genzyme, Baxter and Amgen  at the Pathogen Safety Summit this November.

Pharma IQ's Pathogen Safety Summit is back for its third year to offer the opportunity to learn and hear insights from key regulatory bodies, industry representatives and experts in viral safety on the current viral security strategies and technologies.

As the cost of contamination is huge, both financially and to an organisation's reputation, this event will cover:

  • The latest regulatory updates on viral safety from Arifa Khan, FDA and Dr Wahiba Oualikene-Gonin, AFSAAPS
  • James Gilbert, Biogen Idec and  Lada Laenen, Genzyme,  will share  best practices for the successful evaluation of raw materials
  • Knowledge of the most prevalent pathogens currently being found in biologics from Phil Minor, NIBSC
  • Adam Polermo, Genzyme, present the latest data on the implementation of deep sequencing technologies
  • Rebecca Sheets, NIH, streamlines the viral screening process and rationalise the implementation of the latest technologies

This interactive, senior-level summit will allow organisations to benchmark themselves against the leading experts in biosafety.

Find the full program, event details and registration information at http://www.pathogensafetysummit.com/news, call +44(0)20-7036-1300 or email enquire@iqpc.co.uk.  

Media contact: Nishkala Thiru, +44(0)20-7368-9725, Nishkala.Thiru@iqpc.co.uk or visit http://www.pathogensafetysummit.com/news.

Press are invited to attend this important industry forum, if you would like a complimentary press pass please email Nishkala Thiru at Nishkala.Thiru@iqpc.co.uk    



'/>"/>
SOURCE Pharma IQ
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Magnetic vortex reveals key to spintronic speed limit
2. The Insider Secrets of Back Pain Treatment Revealed
3. Martha Stewart Reveals the Secret Behind her Radiant Skin is Revolutionary Anti-aging BIOEFFECT EGF SERUM
4. Researchers reveal why some pain drugs become less effective over time
5. ORNL microscopy reveals atomic antenna behavior in graphene
6. Carnegie Mellon study reveals potential of manganese in neutralizing deadly Shiga toxin
7. Graphene reveals its magnetic personality
8. Survey Reveals Paternity Questions Loom for More Than One in 10 Americans
9. Imprisoned molecules quantum rattle in their cages
10. Former FDA Inspectors Train Medical Device, Pharmaceutical Companies How to Prepare for FDA Inspections of Their Quality Systems
11. Oncobiologics, Inc. Announces a Collaboration Agreement with XOMA Corporation to Utilize XOMAs Fully Human Antibody Libraries for Their Discovery Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):